Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGRASSET, Leslie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUTELOUP, Vincent
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCACCIAMANI, Federica
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorPELLEGRIN, Isabelle
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorPLANCHE, Vincent
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHÊNE, Geneviève
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDUFOUIL, Carole
dc.date.accessioned2024-09-18T12:40:06Z
dc.date.available2024-09-18T12:40:06Z
dc.date.issued2024-04-01
dc.identifier.issn0028-3878en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201659
dc.description.abstractEnBackground and ObjectivesElevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships with specific cognitive and functional domains require further investigation. We aimed at estimating the associations between AD blood-based biomarkers and the trajectories of distinct cognitive and functional domains over a 5-year follow-up period.MethodsWe conducted a clinic-based prospective study using data from the MEMENTO study, a nationwide French cohort. We selected dementia-free individuals at baseline aged 60 years or older. Baseline measurements of β-amyloid (Aβ) 40 and 42, phosphorylated tau (p-tau181), and neurofilament light chain (NfL) concentrations were obtained using the Simoa HD-X analyzer. Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT), animal fluency, Trail Making Tests A and B, Short Physical Performance Battery (SPPB), and Instrumental Activities of Daily Living were administered annually for up to 5 years. We used linear mixed models, adjusted for potential confounders, to model AD biomarkers’ relation with cognitive and functional decline.ResultsA total of 1,938 participants were included in this study, with a mean (SD) baseline age of 72.8 (6.6) years, and 62% were women. Higher baseline p-tau181 and NfL were associated with significantly faster decline in most cognitive, physical, and functional outcomes (+1 SD p-tau181: βMMSE = −0.055, 95% CI −0.067 to −0.043, βFCSRT = −0.034, 95% CI −0.043 to −0.025, βfluency = −0.029, 95% CI −0.038 to −0.020, βSPPB = −0.040, 95% CI −0.057 to −0.022, and β4IADL = −0.115, 95% CI 0.091–0.140. +1 SD NfL: βMMSE = −0.039, 95% CI −0.053 to −0.025, βFCSRT = −0.022, 95% CI −0.032 to −0.012, βfluency = −0.014, 95% CI −0.024 to −0.004, and β4IADL = 0.077, 95% CI 0.048–0.105). A multiplicative association of p-tau181 and NfL with worsening cognitive and functional trajectories was evidenced. Lower Aβ42/40 ratio was only associated with slightly faster cognitive decline in FCSRT and semantic fluency (+1 SD: β = 0.011, 95% CI 0.002–0.020, and β = 0.011, 95% CI 0.003–0.020, respectively). These associations were not modified by APOE ε4, sex, nor education level.DiscussionIn a memory clinic sample, p-tau181 and NfL, both independently and jointly, are linked to more pronounced cognitive, physical and functional declines. Blood-based biomarker measurement in AD research may provide useful insights regarding biological processes underlying cognitive, physical, and functional declines in at-risk individuals.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.title.enAssociations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort
dc.title.alternativeNeurologyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1212/wnl.0000000000209307en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38626384en_US
bordeaux.journalNeurologyen_US
bordeaux.pagee209307en_US
bordeaux.volume102en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue9en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPHARES_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation Plan Alzheimeren_US
bordeaux.import.sourcehal
hal.identifierhal-04577379
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2024-04-01&rft.volume=102&rft.issue=9&rft.spage=e209307&rft.epage=e209307&rft.eissn=0028-3878&rft.issn=0028-3878&rft.au=GRASSET,%20Leslie&BOUTELOUP,%20Vincent&CACCIAMANI,%20Federica&PELLEGRIN,%20Isabelle&PLANCHE,%20Vincent&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée